A Double Blind, Dose Response Phase II, Multicentre Study of Radium 223 (Alpharadin) for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer Patients

Trial Profile

A Double Blind, Dose Response Phase II, Multicentre Study of Radium 223 (Alpharadin) for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 17 Dec 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004104).
    • 15 Feb 2012 Results published in the European Journal of Cancer.
    • 17 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top